29 results about "Transcription regulator" patented technology

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

Disclosed are systems and methods for detecting extracellular ligands and / or inducing expression of an exogenous or endogenous gene. The disclosed systems and methods typically include and / or utilize (i) first and second exogenous extracellular sensors, and third and fourth exogenous extracellular sensors; and (ii) an expression vector comprising a target gene operably linked to a hybrid promoter sequence. The hybrid promoter sequence of the expression vector includes a minimal promoter for inducing transcription and the hybrid promoter sequence further includes interspaced transcription regulator binding sites upstream of the minimal promoter that bind two or more transcription regulators of the extracellular sensors that are released from the extracellular sensors when the extracellular sensor bind an extracellular ligand.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The invention discloses application of a composition containing lycium barbarum polysaccharide. The lycium barbarum polysaccharide is used for achieving the effects of resisting aging and removing lipofuscin, particularly, the specific lycium barbarum polysaccharide LBP1C can more remarkably reduce the level of transcription factors GATA4, activate key transcription regulatory factors of autophagy, reduce aging-related secretion phenotypes and inhibit accumulation of lipofuscin, and the lycium barbarum polysaccharide LBP1C has the effects of delaying aging, whitening skin and promoting healthy aging.

To provide genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and to provide methods of generating the genetic modified cells.SOLUTION: The universal donor cells comprise at least one genetic modification within or near at least one gene encoding a survival factor, the genetic modification comprising the insertion of a polypeptide encoding a tolerogenic factor. The universal donor cell may further comprise at least one genetic modification within or near a gene encoding one or more MHC-I or MHC-II human leukocyte antigens or components or transcriptional regulators of the MHC-I or MHC-II complexes, the genetic modification comprising the insertion of a polypeptide encoding a second tolerogenic factor.SELECTED DRAWING: Figure 1

Senescent cells are implicated in aspects of age-related decline in health and may contribute to certain diseases. Embodiments include formulations and methods for promoting longevity and treating a senescence associated disease or disorder. Applicants present three distinct classes and multiple associated therapeutic molecules that can function alone or in combination with the other molecules. The classes include transcription regulators, lipid intermediates and microRNAs. Additional embodiments include methods of promoting longevity by administering GRAS substances.

The present invention relates to a gene variant of the transcriptional regulator LysG and a method for producing L-citrulline or L-arginine using same. The gene variant of the transcriptional regulator LysG according to the present invention has protein activity that is altered due to the mutation of one or more bases in the base sequence of a gene encoding the transcriptional regulator LysG, and thus, it is possible to effectively produce L-citrulline or L-arginine from a recombinant microorganism comprising the variant.

The invention relates to the technical field of microorganisms, and particularly discloses a recombinant microorganism for producing adenosine as well as a construction method and application of the recombinant microorganism. According to the method for constructing the recombinant microorganism, compared with an original strain, the recombinant microorganism has the transcriptional regulatory factor BkdR with enhanced activity, and the original strain can be fermented to produce adenosine. The invention further provides a BkdR protein mutant with improved transcriptional level. When the recombinant strain is applied to adenosine fermentation production, higher yield can be obtained, and the fermentation production efficiency is improved.

The present application relates to a novel manganese dependent transcriptional regulator variant polypeptide; a polynucleotide encoding the variant polypeptide; a microorganism comprising the variant polypeptide, a polynucleotide encoding the variant polypeptide, or a vector carrying the polynucleotide; a method for producing L-glutamic acid, said method comprising the step of culturing said microorganism in a culture medium; and the use of said microorganism for the production of L-glutamic acid.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and / or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and / or a different survival factor.

The present invention relates to transcriptional regulator polypeptides, polynucleotides encoding the transcriptional regulator polypeptides, and to nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing a polypeptide of interest in host cells overexpressing the transcriptional regulators, to methods of increasing the oxygen uptake rate and / or decreasing viscosity of the culture broth in a fungal host cell cultivation process, to methods of producing a transcriptional regulator polypeptide, to the use of a transcriptional regulator polypeptide, and to the production of fungal biomass.

The present application relates to a novel manganese-dependent transcriptional regulator mutant polypeptide; a polynucleotide encoding the mutant polypeptide; a microorganism comprising the mutant polypeptide, a polynucleotide encoding the mutant polypeptide, or a vector comprising the polynucleotide; a method for producing L-glutamic acid, the method comprising culturing the microorganism in a medium; and use of the microorganism for producing L-glutamic acid.

The invention discloses an Lrp mutant and application thereof. The invention relates to an Lrp mutant and application thereof in the technical field of biology. The leucine-responsive transcriptional regulatory factor mutant provided by the invention is any one of the following: A1) a protein obtained by mutating the 107th histidine of a protein with an amino acid sequence of SEQ ID No: 1 into tyrosine; a2) a protein which is obtained by substitution and / or deletion and / or addition of amino acid residues on the protein of A1), has 75% or more of identity with the protein of A1) and has the same function as the protein of A1); and A3) a fusion protein obtained by connecting a protein tag to the N terminal or / and the C terminal of A1) or A2). The yield of the engineering strain L-valine is increased through site-specific mutagenesis, and the engineering strain has industrial application value.

The invention provides a combined module for enhancing symbiotic nitrogen fixation capacity of rhizobium and application, and belongs to the technical field of synthetic biology. The combined module for enhancing the symbiotic nitrogen fixation capacity of the rhizobium comprises an inducible promoter element Pi and a transcriptional regulatory factor coding gene tetR, wherein the inducible promoter element Pi and the transcriptional regulatory factor coding gene tetR are sequentially connected; the inducible promoter element Pi specifically responds to a symbiotic nitrogen fixation signal; according to the invention, the combined module is inserted into an initial vector to construct a recombinant expression vector, and the recombinant expression vector is transferred into different soybean rhizobium chassis through a triparental conjugation method to obtain two nitrogen fixation recombinant engineering strains; the recombinant engineering strain can recover the influence of glyphosate stress on the symbiotic nitrogen fixation capability of the rhizobium.

The invention belongs to the field of synthetic biology, and particularly relates to a dynamic regulation and control system based on quorum sensing and application thereof. The gene comprises a constitutive promoter, a signal molecule AHLs synthetase coding gene esaI, a segment of RBS sequence, a transcriptional regulatory factor synthetase coding gene esaRI70V, a quorum sensing target promoter PesaS and a threonine synthesis key gene thrB regulated by the quorum sensing target promoter PesaS. Accurate dynamic regulation and control of a threonine synthesis route are realized by adjusting the strength of the constitutive promoter in the system, addition of necessary amino acid threonine in the fermentation process of escherichia coli engineering bacteria is eliminated, an inducer does not need to be added, the regulation and control complexity and the fermentation cost in the fermentation process are effectively reduced, and the method is suitable for large-scale industrial production. The method has good production and application values.

The present disclosure generally relates to multi-chain chimeric polypeptides or receptors having different polypeptide chains that associate post-translational to enable simultaneous activation of a signaling domain and release of a transcriptional regulatory factor following binding of a ligand. The disclosure also provides nucleic acid constructs, recombinant cells, vectors, pharmaceutical compositions and methods of treatment comprising the multi-chain chimeric polypeptides of the disclosure. The present disclosure also provides methods for simultaneous induction of T cell signaling and gene modulation in T cells.

The present disclosure generally relates to multi-chain chimeric polypeptides or receptors having distinct polypeptide chains that associate post-translationally to enable the simultaneous activation of the signaling domain and the release of a transcriptional regulator upon binding of a ligand. The disclosure also provides nucleic acid constructs, recombinant cells, vectors, pharmaceutical compositions, and methods of treatment including the multi-chain chimeric polypeptides of the disclosure. The disclosure further provides methods for simultaneously inducing T cell signaling and gene regulation in a T cell.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

This invention provides a combined module and its application for enhancing the symbiotic nitrogen fixation ability of rhizobia, belonging to the field of synthetic biology. The combined module for enhancing the symbiotic nitrogen fixation ability of rhizobia includes sequentially connected inducible promoter elements Pi that specifically respond to symbiotic nitrogen fixation signals and elements from... Sinorhizobium Fred transcriptional regulatory factor encoding genes tetR The present invention inserts the combined module into the initial vector to construct a recombinant expression vector, and then uses the triparental conjugation method to transfer the recombinant expression vector into different soybean rhizobium chassis to obtain two nitrogen-fixing recombinant engineered strains. Compared with wild-type rhizobium, the recombinant engineered strains of the present invention can restore the effect of glyphosate stress on the symbiotic nitrogen-fixing ability of rhizobium.

The invention relates to a genetic engineering strain for producing human milk oligosaccharide and application of the genetic engineering strain. According to the genetic engineering strain, bacillus subtilis is used as a chassis strain; a transcriptional regulatory factor gene ganR for coding a galactan degradation operon, a galactooligosaccharide binding protein gene ganS, a galactooligosaccharide transport system permease protein gene ganP, a galactooligosaccharide transport system permease protein gene ganQ, a beta-galactosidase gene ganA, an endonucle-beta-1, 3, 4, 5, 6, 7, 8-tetramethyl-beta-1, 3, 4-tetramethyl-beta-1, 3, 4-tetramethyl-beta-1, 3, 4-tetramethyl-beta-1, 3, 4-tetramethyl-beta-1, 3, 4-tetramethyl-beta-1, 3, 4 and one or more of 1, 4-galactanase genes ganB is / are selected from the group consisting of 1, 4-galactanase genes The genetic engineering strain provided by the invention can effectively inhibit and utilize products in the fermentation process, so that the fermentation yield of target products is effectively improved.

The present application pertains to a novel manganese-dependent transcription regulator variant polypeptide; a polynucleotide encoding the variant polypeptide; a microorganism containing the variant polypeptide, a polynucleotides encoding the variant polypeptide, or a vector carrying the polynucleotide; a method for producing L-glutamic acid, the method including a step of culturing the microorganism in a medium; and a use of the microorganism for the production of L-glutamic acid.

The present application relates to a microorganism having weakened activity of a LacI DNA-binding transcriptional regulator protein and a method for producing L-glutamic acid using the same. The Corynebacterium microorganism of the present application having weakened activity of a LacI DNA-binding transcriptional regulator protein has significantly increased L-glutamic acid producing ability, and its use makes it possible to produce L-glutamic acid at a higher yield than existing microorganisms.

The present application relates to the field of agricultural biotechnology, and in particular to a method for constructing an engineered strain of Rhodopseudomonas palustris for producing inositol using glucose, glycerol and CO2 as carbon sources, and the strain. The present application mutates the gene nagE encoding N-acetylglucosamine-specific phosphotransferase system in the genome of Rhodopseudomonas palustris (G265R), and knocks out the gene nagR encoding a transcriptional regulator of the GntR family, so that Rhodopseudomonas palustris can efficiently utilize glucose. On this basis, an engineered strain of Rhodopseudomonas palustris H16 is constructed for synthesizing inositol using renewable substrates (glucose and glycerol) and CO2 as carbon source. Based on this technology, not only the synthesis of bioactive substances can be achieved, but also a method for efficiently eliminating greenhouse gases in the atmosphere.

The present disclosure relates to transcriptional signatures obtained on a set of genes comprising any of 220 to 249 of a set of genes (1) and any of 210 to 233 of a set of genes (2) from a TEAD-500 signature and its use for determining the TEAD-activity of a cancer. The transcriptional signatures are useful in a variety of applications, including, predicting the likelihood that a subject will respond to a TEAD-pathway inhibitor treatment, selecting patients for clinical trials, assessing efficacy of TEAD-pathway inhibitor molecules, and prognosing survival, response to, and benefit from anti-TEAD pathway treatments.

The application discloses an Lrp mutant and application thereof. The application relates to an Lrp mutant and application thereof in the field of biotechnology. The leucine-responsive transcriptional regulator mutant provided by the application is any one of the following: A1) a protein obtained by mutating a histidine at the 107th position of a protein with an amino acid sequence of SEQ ID No: 1 into tyrosine; A2) a protein obtained by substituting, deleting and / or adding amino acid residues of the protein of A1) and having 75% or more identity with the protein shown in A1) and the same function; and A3) a fusion protein obtained by connecting a protein tag to the N terminal or / and C terminal of A1) or A2). The yield of L-valine of the engineering strain is improved through site-directed mutation, and the application has industrial application value.

The present disclosure relates generally to chimeric antigen receptors (e.g., the synthetic Notch receptors disclosed herein) that contain two or more human or humanized transcriptional regulators to augment their function to regulate cell transcription. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and / or for the treatment of various health conditions or diseases, such as cancers.

Provided is a method for increasing the productivity of secondary metabolites such as antibiotics in a microorganism. In particular, provided is a method to improve the productivity of secondary metabolites in a microorganism by inactivating or reducing the expression of FadR transcription regulator and Srb RNA binding protein of said microorganism.